LC Sciences

lcsciences.com

LC Sciences is a global biotechnology company providing products and services to genomics and proteomics researchers across an array of markets for nucleic acid/protein analysis, biomarker-discovery and drug development. Our innovative products and comprehensive services are based on several unique, core technology platforms developed by the scientists here at LC Sciences. A wide range of microarray service products are based on our µParaflo® microfluidic on-chip synthesis technology. This technology enables us to provide unique and customizable arrays of oligonucleotides, peptides, and their analog molecules. Our line of microarray services includes microRNA profiling, custom oligonucleotide (aptamer) screening, and peptide arrays for epitope mapping, protein kinase substrate profiling, and phosphopeptide binding assays.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SIEMENS AND EXYTE JOIN FORCES ON MODULAR BIOTECH FACILITIES

Siemens | June 11, 2020

news image

Siemens, a process automation specialist, and Exyte, a biopharmaceutical manufacturing facility provider, have joined forces to offer end-to-end solutions for the biopharmaceutical industry.Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities. Siemens and Exyte are committed to tackle those challenges. Together, they...

Read More

XYLYX BIO RELEASES NORMAL AND FIBROTIC NATIVECOAT™ ECM SUBSTRATES INCREASE PREDICTIVENESS OF HIGH THROUGHPUT COMPOUND SCREENING

Xylyx Bio | August 27, 2020

news image

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...

Read More

MEDTECH, INDUSTRIAL IMPACT

GENERATE BIOMEDICINES EXPANDS LEADERSHIP TEAM WITH CHIEF DIGITAL OFFICER

Generate Biomedicines | December 07, 2022

news image

Generate Biomedicines announced that Dimitris Agrafiotis, Ph.D., FRSC, has been appointed Chief Digital Officer. He will lead multidisciplinary teams across technology, data science, automation, and digital transformation to support the rapid growth of the machine learning-powered biotech. Dr. Agrafiotis brings deep expertise at the intersection of digital technology, data science, and life sciences spanning the entire R&D continuum across venture-funded biotech, big pharma, a...

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

CBM, STOIC BIO AND NUCLEUS BIOLOGICS ANNOUNCE STRATEGIC ALLIANCE

The Center for Breakthrough Medicines | March 13, 2023

news image

Nucleus Biologics and Stoic Bio have teamed up to form a supply agreement with the Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization that aims to accelerate the development and manufacture of advanced therapies. Under the agreement, Nucleus Biologics will become CBM's selected supplier of cell culture media and other biological solutions, ensuring a consistent supply of this critical material with tighter quality control measures. ...

Read More
news image

SIEMENS AND EXYTE JOIN FORCES ON MODULAR BIOTECH FACILITIES

Siemens | June 11, 2020

Siemens, a process automation specialist, and Exyte, a biopharmaceutical manufacturing facility provider, have joined forces to offer end-to-end solutions for the biopharmaceutical industry.Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities. Siemens and Exyte are committed to tackle those challenges. Together, they...

Read More
news image

XYLYX BIO RELEASES NORMAL AND FIBROTIC NATIVECOAT™ ECM SUBSTRATES INCREASE PREDICTIVENESS OF HIGH THROUGHPUT COMPOUND SCREENING

Xylyx Bio | August 27, 2020

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...

Read More
news image

MEDTECH, INDUSTRIAL IMPACT

GENERATE BIOMEDICINES EXPANDS LEADERSHIP TEAM WITH CHIEF DIGITAL OFFICER

Generate Biomedicines | December 07, 2022

Generate Biomedicines announced that Dimitris Agrafiotis, Ph.D., FRSC, has been appointed Chief Digital Officer. He will lead multidisciplinary teams across technology, data science, automation, and digital transformation to support the rapid growth of the machine learning-powered biotech. Dr. Agrafiotis brings deep expertise at the intersection of digital technology, data science, and life sciences spanning the entire R&D continuum across venture-funded biotech, big pharma, a...

Read More
news image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

CBM, STOIC BIO AND NUCLEUS BIOLOGICS ANNOUNCE STRATEGIC ALLIANCE

The Center for Breakthrough Medicines | March 13, 2023

Nucleus Biologics and Stoic Bio have teamed up to form a supply agreement with the Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization that aims to accelerate the development and manufacture of advanced therapies. Under the agreement, Nucleus Biologics will become CBM's selected supplier of cell culture media and other biological solutions, ensuring a consistent supply of this critical material with tighter quality control measures. ...

Read More